Pancreatic cancer
Conditions
Interventions
Experimental Group:Irreversible Electroporation Ablation Combined with Chemotherapy
Sponsors
Sun Yat-sen University Cancer Center
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Patients who have received at least two courses of chemotherapy, have been evaluated as Stable disease (SD), Partial response or Complete response after imaging examination, and simultaneously meet the following criteria can be enrolled in the trial: 1) Age: 18 to 80 years old, gender not limited. 2) It was clearly diagnosed as primary pancreatic ductal adenocarcinoma by histology or cytology, and clinically diagnosed as liver metastasis of pancreatic cancer. 3) The diameter of the primary pancreatic tumor is no more than 5cm, and the number of intrahepatic metastatic lesions is no more than 5, with the maximum diameter of a single lesion being no more than 3cm. 4) Those who have not received local ablation treatment before; 7 5)Karnofsky Physical Strength Score (KPS) >=80 or ECOG 0-1 points; 6) Those who voluntarily participate and sign the informed consent form, undergo examinations and regular follow-ups as stipulated in the plan, and sign the informed consent form;
Exclusion criteria
Exclusion criteria: 1) Expected survival time <= 6 months. 2) History of prior local ablation therapy. 3) Presence of severe complications, such as active massive gastrointestinal bleeding, perforation, or intestinal obstruction. 4) Tumor invasion of the stomach wall or duodenum. 5) History of severe arrhythmia, coronary heart disease, sick sinus syndrome, or recent occurrence of extensive myocardial infarction; or implantation of a permanent cardiac pacemaker or other metal implants. 6) Presence of metal stents or other metal implants within 2.5 cm of the ablation area. 7) Severe cardiac, pulmonary, or renal insufficiency, or inability to tolerate general anesthesia. 8) Use of anticoagulant medications within one week prior to the procedure or abnormal coagulation function. 9) Acute infection or acute exacerbation of a chronic infection. 10) Pregnant or lactating women, or women of childbearing potential who refuse to use appropriate contraception. 11) History of epilepsy, psychiatric disorders, or mental illness that may affect the understanding of informed consent or the implementation of the trial protocol. 12) Judged by the investigator as unsuitable for enrollment or unwilling to accept potential surgical intervention.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Quality of Life (QoL) Assessment in Cancer Patients;Rate of Perioperative Complication;Perioperative Mortality; | — |
Countries
China
Contacts
Public ContactShengping Li
Sun Yat-sen University Cancer Center
Outcome results
None listed